Beam Therapeutics vs Immunitybio
Beam Therapeutics is the larger business, with $140m of revenue in fiscal 2025 against $113m for Immunitybio (1.2 times as much). Immunitybio grew faster (668.3% against 120.0%). Beam Therapeutics kept more of each dollar of sales as profit: a net margin of -57.2% against -310.2%.
| Latest fiscal year | Beam TherapeuticsBEAM, 2025 | ImmunitybioIBRX, 2025 |
|---|---|---|
| Revenue | $140m | $113m |
| Revenue growth | 120.0% | 668.3% |
| Net income | −$80.0m | −$351m |
| Operating margin | -274.6% | -226.0% |
| Net margin | -57.2% | -310.2% |
| Return on equity | -8.1% | — |
| Free cash flow | −$360m | −$309m |
| Cash | $295m | $88.3m |
| Total debt | $0 | $326m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 511 | 691 |
| Market value | $2.74bn | $8.69bn |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 31 sales | 0 buys, 16 sales |